AI in Medicine — Cancer & Rare Disease — 2026-09-30 (Wed) Morning News

Latest news on AI and cancer treatment

Overview

There is a noticeable movement toward the use of AI in the field of diagnostic imaging (second lead breast imaging, liquid biopsy as a substitute for liver biopsy, and spatial biomarker analysis for pathology). In breast cancer, there were reports on stratification of recurrence risk, while in the drug discovery field, the focus was on preclinical and corporate trends such as antibody exploration and partnerships. Specific information regarding announcements of approval/designation by regulatory authorities (FDA/EMA/PMDA) and clinical trial registration is not within the scope of this collection.

Breast cancer

- Target: HR+/HER2- breast cancer patients. It was reported that the AI score extracted from MRI can stratify recurrence risk in addition to existing standard prognostic factors (tumor size, grade, etc.) [Vera Health]. There is only a single headline information, and the target size and verification method (retrospective/prospective, single center/multicenter) are unclear. - It was reported that some medical institutions are using AI to replace radiologists for the 2nd read of breast images [Radiology Business]. Efficacy indicators (sensitivity, specificity, etc.) are not listed in the heading. - Flatiron Health expands AI-powered real-world dataset targeting breast cancer and NSCLC to UK, Germany, and Japan [BioSpace] Expanding the data base rather than making clinical validity claims.

lung cancer

We only confirmed that NSCLC (non-small cell lung cancer) is included in the Flatiron Health real-world data expansion mentioned above. There are no headlines regarding new findings regarding specific diagnostic accuracy or treatment selection.

Malignant brain tumor

- Article reporting that optical (photonic) biosensors incorporating AI may be useful in detecting glioblastoma tissue [azosensors.com]. The clinical application stage is unclear from the headline (it is assumed to be at the technology development/basic research stage, but it is not stated). - "Sheinelle Jones Horrified by Convincing AI Fake Featuring Her Children" [Reality Tea] is entertainment news about AI-generated deep fakes and has nothing to do with cancer treatment or medical AI. It was determined that the data was collected in error and was excluded from the analysis.

Leukemia/lymphoma

No applicable information

Colon cancer/digestive organ

"Latest hospital AI deployments in Singapore and more briefs" [Healthcare IT News] is an overview article about the introduction of AI in hospitals in Singapore, but the headline does not contain any specific content specific to the detection of colorectal cancer or gastrointestinal cancer.

Rare cancer

No applicable information

Diagnosis/Pathology/Image

- The use of AI in liquid biopsies was reported as a "hot field" [GlobeNewswire, citybiz (BCC Research)]. This is a report on market and investment trends, and clinical data such as detection sensitivity are not listed in the headline. - Haga Bioscience and Imagenomix enter into partnership to utilize AI in spatial biomarker analysis in cancer pathology [Genome Web]. This is a technical partnership announcement, and there are no figures regarding clinical performance. - Diagnostic imaging AI company reports 15% headcount reduction and annual revenue growth to $28 million [Radiology Business]. This is management and business trends, not information on clinical effectiveness. - The adoption of AI for the second lead in breast imaging (same case as 2. above) was also featured in an industry summary article [Radiology Business]. In the same article, ``KOA (knee arthropathy) treatment using low-dose radiation therapy'' is not covered because it is unrelated to cancer.

Treatment selection/drug discovery

- It was reported that the pharmaceutical industry as a whole is moving to strengthen the use of AI to reduce costs and development times [Reuters]. This is an article about industry trends, with no description of individual drugs or stages. - Announcement that Massive Bio has been recognized by TIME magazine in the Health Tech AI and Data Analytics category [businesswire.com]. This is a corporate award and does not indicate the clinical stage of a specific drug. - A method to verify antibodies within a few days from predictions made by AI was reported [News-Medical]. This is a technical report at the preclinical (antibody discovery/verification) stage, not information at the clinical trial stage.

Regulations/Approval

No applicable information

Clinical trial implementation status

No relevant information (Specific data regarding trial name, target cancer type, phase, and registration status from ClinicalTrials.gov is not provided at this time)

Japanese movements

Flatiron Health expands the provision of AI-based real-world datasets for breast cancer and NSCLC to Japan [BioSpace]. The headline does not mention any unique developments regarding medical treatment, approval, or clinical trials in Japan.

Remarks from VIPs

The list of important people to be tracked is empty, and there are no quotations with titles in the headlines, so there is no relevant information.

Latest news on AI and rare and incurable diseases

Overview

Only two headlines were provided, and both of them were peripheral articles related to systems and employment, rather than direct information on diagnostics and therapeutic drugs. There are no headlines indicating specific progress regarding diagnostic and therapeutic drugs for designated intractable diseases.

Diagnosis of rare diseases

No applicable information

Gene analysis/genome

No applicable information

Development of therapeutic drugs

No applicable information

Nerve/muscular diseases

No applicable information

Immunology/Collagen disease

No applicable information

Rare metabolic/endocrine diseases

No applicable information

System/Patient Support

- Asura Co., Ltd., which supports the social participation of people with disabilities through "welfare x logistics," realizes AI native recruitment with "MyTalent" (Nico Nico News): This article appears to be an introduction to AI-based services related to employment of people with disabilities, but it is not possible to confirm whether the article is a target disease or a designated intractable disease just by looking at the headline.

Japanese movements

- Report that there was a discussion on the actual state of AI utilization at the Japanese Society of Religious Studies academic conference (Chugai Nippo). The headline does not suggest a direct connection to rare or intractable diseases, but rather appears to be in the context of AI ethics and social debate.

Remarks from VIPs

No applicable information